<DOC>
	<DOCNO>NCT01969747</DOCNO>
	<brief_summary>Placebo-controlled , double blind ( triple-dummy technique ) , randomise parallel design comparison three oral dos ( 2.5 mg , 10 mg , 25 mg ) empagliflozin patient T1DM adjunctive therapy insulin 28 day . Patients undergo 14-day open-label placebo run-in period randomisation . Background insulin therapy keep stable first 7 day treatment period freely adjust thereafter .</brief_summary>
	<brief_title>Empagliflozin add-on Insulin Type 1 Diabetes Mellitus Over 28 Days</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Signed date write informed consent Male female patient receive insulin treatment T1DM least 12 month Cpeptide &lt; 1.5 ng/mL Age 18 65 year HbA1c 7.5 % 10.5 % Multiple daily injection ( MDI ) type insulin Willing follow establish individualized carbohydrate counting method insulin administration algorithm Body Mass Index 18.5 35.0 kg/m2 Estimated glomerular filtration rate 60 150 mL/min/1.73 mÂ² Able willing perform study assessment accord investigator 's judgement Compliance trial drug administration 80 % 120 % runin period Willing take paracetamol contain drug trial Exclusion criterion : Acute symptomatic urinary tract infection genital infection , chronic recurrent cystitis History type 2 diabetes mellitus , maturity onset diabetes young ( MODY ) , pancreatic surgery chronic pancreatitis Pancreas , pancreatic islet cell renal transplant recipient Type 1 diabetes mellitus treatment antihyperglycaemic drug except insulin within last 3 month history clinically relevant hypersensitivity Occurrence hypoglycaemia require hospitalization treatment emergency physician paramedic within last 3 month Hypoglycaemia unawareness frequent episode unexplained hypoglycaemia Occurrence diabetic ketoacidosis require hospitalization treatment emergency physician paramedic within last 12 month History macrovascular disease include cardiovascular , cerebrovascular peripheral artery disease Autonomic neuropathy gastroparesis Brittle diabetes Liver disease Treatment antiobesity drug , surgery aggressive diet regimen lead unstable body weight Treatment systemic corticosteroid Change dose thyroid hormone within last 6 week plan change initiation therapy Medical history cancer treatment cancer last five year Blood dyscrasia disorder cause haemolysis unstable red blood cell Alcohol drug abuse would interfere trial participation ongoing clinical condition would jeopardize patient 's site personnel 's safety study compliance Intake investigational drug another trial within last 30 day Not able understand comply study requirement Premenopausal woman nurse pregnant childbearing potential practising acceptable method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>